Keppra XR (Levetiracetam Extended-Release Tablets)
levetiracetam - Drug Summary
CLASSES
Anticonvulsants, SV2A Inhibitors
DEA CLASS
Rx
DESCRIPTION
Pyrrolidine derivative and brivaracetam analog
For certain types of partial, myoclonic, and generalized tonic-clonic seizures as adjunct therapy
Monitor for emerging or worsening suicidal thoughts/behavior and depression
COMMON BRAND NAMES
Keppra, Keppra XR, Roweepra
HOW SUPPLIED
Keppra XR/Levetiracetam Oral Tab ER: 500mg, 750mg
Keppra/Levetiracetam Oral Sol: 1mL, 100mg
Keppra/Levetiracetam/Roweepra Oral Tab: 250mg, 500mg, 750mg, 1000mg
Spritam Oral Tab Orally Dis: 250mg, 500mg, 750mg, 1000mg
DOSAGE & INDICATIONS
For the adjunctive treatment of partial seizures.
NOTE: Treatment may be initiated with IV or PO therapy.
Oral dosage (solution)
Adults and Adolescents > = 16 years
Initially, 500 mg PO twice daily. Increase the dose every 2 weeks by 500 mg/dose (i.e., 1,000 mg/day) increments to a maximum recommended dosage of 1,500 mg PO twice daily (Max: 3,000 mg/day). Doses greater than 3,000 mg/day have been used in open-label studies for 6 months and longer; however, there is no evidence that doses greater than 3,000 mg/day provide additional benefit.
Children and Adolescents 4 to 15 years
Initially, 10 mg/kg/dose PO twice daily. Increase the dose every 2 weeks by 10 mg/kg/dose (i.e., 20 mg/kg/day) increments to the recommended dose of 30 mg/kg/dose PO twice daily. If the patient cannot tolerate this dose, it may be reduced. In clinical trials, the mean daily dose was 44 mg/kg/day PO (Max: 3,000 mg/day).
Infants and Children 6 months to 3 years
Initially, 10 mg/kg/dose PO twice daily. Increase the dose every 2 weeks by 10 mg/kg/dose (i.e., 20 mg/kg/day) increments to the recommended dose of 25 mg/kg/dose PO twice daily. If the patient cannot tolerate this dose, it may be reduced. In clinical trials, the mean daily dose was 47 mg/kg/day PO.
Infants 1 to 5 months
Initially, 7 mg/kg/dose PO twice daily. Increase the dose every 2 weeks by 7 mg/kg/dose (i.e., 14 mg/kg/day) increments to the recommended dose of 21 mg/kg/dose PO twice daily. If the patient cannot tolerate this dose, it may be may be reduced. In clinical trials, the mean daily dose was 35 mg/kg/day PO.
Oral dosage (immediate-release tablets and fast-melting tablets)
Adults and Adolescents >= 16 years
Initially, 500 mg PO twice daily. Increase dose q2 weeks by 500 mg/dose (i.e., 1,000 mg/day) increments to a maximum recommended dosage of 1,500 mg PO twice daily (Max: 3,000 mg/day). Doses greater than 3,000 mg/day have been used in open-label studies for 6 months and longer; however, there is no evidence that doses greater than 3,000 mg/day provide additional benefit.
Children and Adolescents 4 to 15 years weighing > 40 kg
Initially, 500 mg PO twice daily. Increase the dose every 2 weeks by 500 mg/dose (i.e., 1,000 mg/day) increments to a maximum recommended dose of 1,500 mg PO twice daily (Max: 3,000 mg/day).
Children and Adolescents 4 to 15 years weighing 20 to 40 kg
Initially, 250 mg PO twice daily. Increase the dose every 2 weeks by increments of 250 mg/dose (i.e., 500 mg/day) to a maximum recommended dose of 750 mg PO twice daily (Max: 1,500 mg/day).
Children and Adolescents 4 to 15 years weighing < 20 kg
Tablets are not recommended. See dosing for oral solution.
Oral dosage (extended-release tablets)
Adults, Adolescents, and Children >= 12 y